Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
06:03am, Monday, 02'nd Aug 2021
Following the June update that allowed for a lower dose of REGEN-COV, the FDA has again expanded emergency use authorization for the investigational COVID-19 antibody cocktail. REGEN-COV (casirivi
Roche's Faricimab US Application For Ocular Diseases Under Priority Review
08:03am, Thursday, 29'th Jul 2021
The FDA has accepted Roche Holding AG's (OTC: RHHBY) Biologics License Application seeking approval for faricimab in neovascular of wet age-related macular degeneration (nAMD) and diabetic macular
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA), under Priority
Basel, 29 July 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine (NEJM) has published data from FIREFISH Part 2, a pivotal global study evaluating th
The Hanover Insurance Group, Inc. (THG) CEO Jack Roche on Q2 2021 Results - Earnings Call Transcript
04:26pm, Wednesday, 28'th Jul 2021
The Hanover Insurance Group, Inc. (THG) CEO Jack Roche on Q2 2021 Results - Earnings Call Transcript
Will Roche's Stock Rebound After A 4% Fall Following Its H1 Results?
10:00am, Tuesday, 27'th Jul 2021
The stock price of Roche Holding's ADR reached its all-time high of $48 just last week, before a recent sell-off in the stock, which led to over a 4% drop in its price to levels of $46 currently. Much
Roche Holding AG (RHHBY) CEO Severin Schwan on Q2 2021 Results - Earnings Call Transcript
07:55pm, Thursday, 22'nd Jul 2021
Roche Holding AG (RHHBY) CEO Severin Schwan on Q2 2021 Results - Earnings Call Transcript
Roche Puts Alzheimer's Candidate, Gantenerumab In Spotlight; In Dialogue with FDA: Reuters
01:31pm, Thursday, 22'nd Jul 2021
Roche Holding AG (OTC: RHHBY) is reportedly talking to the FDA about its Alzheimer's disease drug candidate, gantenerumab. CEO Severin Schwan declined to speculate on the outcome of the talks, Re
Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars
12:14pm, Thursday, 22'nd Jul 2021
Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.
Roche Is Discussing Alzheimer's Drug With FDA Following Regulators Controversial Approval Of Biogen's Aduhelm, CEO Says
06:48am, Thursday, 22'nd Jul 2021
Aduhelm is expected to be a bestseller for Biogen and was the first Alzheimer's drug to be granted “accelerated approval,” a decision the regulator's experts criticized and said there was not enou
Roche CEO: Very Confident Will Reach Our Outlook
04:41am, Thursday, 22'nd Jul 2021
Jul.22 -- Severin Schwan, chief executive officer at Roche Holding AG, discusses company earnings, the outlook for covid tests in the second half of the year and the timeline for the firm's covid anti
Covid testing demand is on the decline, Roche CEO says
04:01am, Thursday, 22'nd Jul 2021
Roche CEO Severin Schwan discusses the pharmaceutical company's second-quarter earnings, the outlook for Covid-19 testing in the second half of the year, and treatments in the pipeline.
Roche keeps outlook as diagnostics power sales growth
01:16am, Thursday, 22'nd Jul 2021
Roche posted first-half net profit of 8.22 billion Swiss francs ($8.96 billion) as sales rose 8% at constant exchange rates to a better-than expected 30.71 billion francs.
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results
01:00am, Thursday, 22'nd Jul 2021
Basel, 22 July 2021
15 European Dividend Aristocrats to Diversify Your Portfolio
01:47pm, Wednesday, 21'st Jul 2021
Plenty of investors focus in on dividends, and dividend aristocrats, but if those investors only look in the U.S. they could be missing out. The post 15 European Dividend Aristocrats to Diversify Your
